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A Tissue Engineering Approach for Prenatal Closure
of Myelomeningocele with Gelatin Sponges
Incorporating Basic Fibroblast Growth Factor
Miho Watanabe, M.D.,1,2 Jun-ichiro Jo, Ph.D.,3 Antonetta Radu,1 Michio Kaneko, M.D., Ph.D.,2
Yasuhiko Tabata, Ph.D., D.Med.Sci., D.Pharm.,3 and Alan W. Flake, M.D.1
Myelomeningocele (MMC) is a common and devastating malformation. Although fetal surgical closure may
improve outcome, a less invasive approach that can be applied earlier in gestation is desirable. The objective of
this study was to evaluate the therapeutic feasibility of a tissue engineering approach for prenatal coverage of
MMC. A gelatin hydrogel composite combining a gelatin sheet and gelatin sponge was prepared with or without
basic fibroblast growth factor incorporation, and applied prenatally to retinoic-acid-induced fetal MMC in the rat
model. Most of the composites were adherent to the MMC within the amniotic fluid environment with the help
of cyanoacrylate adhesive. Histological examination revealed cells layered over the composites with associated
extracellular matrix as well as cellular ingrowth into the sponges. The layer over the composite was composed of
mixed nonepithelial and epithelial cells with the extracellular matrix consisting of collagen type I and hyaluronic
acid. The tissue inside the sponge consisted of nonepithelial cells and hyaluronic acid. Epidermal ingrowth
underneath the sponges and neovascularization into the sponges occurred and were significantly increased by
the incorporation of basic fibroblast growth factor. Although further development is needed, this study supports
the therapeutic potential of a tissue engineering approach for prenatal coverage of MMC.
Introduction
Myelomeningocele (MMC) is one of the most com-mon congenital malformations and represents the
most severe form of spina bifida. MMC results from failure of
closure of the neural tube with secondary exposure of the
neural elements. A ‘‘two-hit’’ hypothesis has been proposed to
explain the neurologic damage observed in children with
MMC. The first ‘‘hit’’ is the primary failure of neurulation and
the second ‘‘hit’’ is due to the chemical and mechanical injury
of the exposed neural elements that occurs throughout the
remainder of gestation.1 The compelling rationale for prenatal
closure of the defect is to prevent the second hit, that is,
damage to the spinal cord from exposure to the intrauterine
environment. To test this rationale, an National Institutes of
Health–sponsored clinical trial comparing prenatal closure of
the defect with standard postnatal treatment is currently un-
derway (Management of Myelomeningocele study). Before
initiation of this trial, nonrandomized or controlled prelimi-
nary studies documented a reversal of hindbrain herniation, a
reduced incidence of shunt-dependent hydrocephalus, and
better than anticipated lower extremity neuromotor function
in a subset of patients. However, many children after fetal
surgery have significant residual deficit.2–9 In many cases, the
procedure is performed relatively late in gestation, after
damage to the neural elements has already occurred. It is also
possible that the surgery itself, either directly or indirectly,
through scarring and tethering of the cord contributes to the
neural injury. Finally, open fetal surgery involves a major
operative procedure placing the mother at significant risk.
Therefore, a less invasive approach that could be applied
earlier in gestation would theoretically increase the benefit
and reduce the risk of fetal treatment.
As the MMC defect can be viewed as a tissue defect, we
hypothesized that it may be possible to apply tissue engi-
neering techniques to achieve tissue coverage of the defect
and thereby prevent the progressive destruction of the ex-
posed neural elements.10–13 If a tissue-engineered construct
could be applied using fetoscopy or ultrasound-guided in-
jection, the treatment would be much less invasive than
current treatments and could be applied earlier in gestation
to maximize preservation of neural elements.14
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The objective of this study was to demonstrate proof of
principle that a gelatin-hydrogel-based scaffold containing
basic fibroblast growth factor (bFGF) can adhere to the MMC
defect in the rat model of retinoic-acid (RA)-induced fetal




Gelatin with an isoelectric point of 5.0 (molecular weight¼
99,000) was prepared through alkaline processing of bovine
bone (Nitta Gelatin, Osaka, Japan). The bFGF was supplied
by Kaken Pharmaceutical (Tokyo, Japan).
Preparation of gelatin hydrogels and sponge
Gelatin sponges and sheets were prepared by dehy-
drothermal crosslinking according to the method previously
reported.15,16 Briefly, the gelatin sponges were created by
mixing a 3 w=v% solution of aqueous gelatin at 5000 rpm for
3 min with a homogenizer (Auto Cell Master CM-2000; As
One, Osaka, Japan) at room temperature, and then casting
the mixture in a polypropylene dish of 6060 cm2. The casts
were frozen in liquid nitrogen for 20 s, and then transferred
to a 208C freezer for 12 h, followed by freeze-drying (TF5-
85ATANN; Takara, Tokyo, Japan). The casts were then put
into a vacuum drying oven (DN-30S; Sato Vac, Tokyo, Japan)
at 1608C for 24 h. The dehydrothermal crosslinked gelatin
sponges were punched out to obtain 1-mm-thick discs with a
3.5 mm diameter and then sterilized with ethylene oxide gas
(EOG; EOG sterilizer SA-160; Elk, Osaka, Japan) (Fig. 1A). A
3 w=v% solution was chosen after comparison with 1, 5, and
7 w=v% solutions because it provided an optimal pore size
for proliferation and migration of mesenchymal stromal cells
and fetal fibroblasts in vitro as determined by colorimetric
3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay. Pore size was determined by examination of
sectioned sponges under scanning electron microscopy.
Preparation of the gelatin sheet
A bicomponent mold was constructed as follows. A
3.5 mm biopsy punch (Biopsy Punch; Kai Industries, Gifu,
Japan) was used to punch out 36 holes in a Teflon sheet
(PTFE; As One) in a 49 grid. A second Teflon sheet of the
same size was glued underneath the first one representing
the bottom mold. The top mold was constructed by gluing
the 36 holes that were punched out from the Teflon sheet
onto a plastic sheet of the same size, in the exact 49 grid
locations matching the holes in the bottom mold (Fig. 1B). A
5 w=v% solution of gelatin solution was then poured into the
bottom mold and the top mold was placed upside-down on
top of it to create circular gelatin sheets designed to match
the shape of the MMC defect with a central inset to accom-
modate insertion of the gelatin sponge. The filled molds were
FIG. 1. Preparation of the gelatin composite. (A) The 3.5-mm-diameter gelatin sponge and the cross-sectional view by
scanning electron microscopy. The pores range from 250 to 400 mm. (B) A bicomponent mold consisting of fitted internal and
external components to construct the gelatin sheets. (C) The appearance of the dehydrothermal crosslinked gelatin sheet
formed with the bicomponent mold. (D) Schematic diagrams of the gelatin composite composed of a gelatin sheet and a
gelatin sponge and the assembled composite. Color images available online at www.liebertonline.com=ten.
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kept in a refrigerator at 48C until the gelatin solution was
completely air-dried. The molded gelatin was peeled off of
the cast and put into a vacuum drying oven at 1608C for 24 h
for crosslinking. The finished product was harvested by
cutting around each of the grooves and bumps to form 36
individual gelatin sheets that fit the shape of the MMC defect
(Fig. 1C). The sheets were sterilized with EOG.
Preparation of bFGF-incorporated gelatin sponges
and gelatin composites
Aqueous solution containing 10mg=mL of bFGF (10 mL)
was applied to a freeze-dried gelatin sponge and left over-
night at 48C. The prepared bFGF-incorporated gelatin
sponges were used without washing. Each gelatin sponge
was fitted within the recessed area of the gelatin sheet to
make a gelatin composite just before use (Fig. 1D).
Animal experiments
All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee at The Children’s
Hospital of Philadelphia or the Committee on Animal Care
and Use at Kyoto University and followed guidelines set
forth in the National Institutes of Health Guide for Care and
Use of Laboratory Animals.
Animal preparation and RA exposure
The procedures for creating MMC defects in fetal rats have
been described by us previously.14 Briefly, time-dated
Sprague-Dawley rats (Charles River Laboratories, Wilming-
ton, MA, and Shimizu Laboratory Supplies, Kyoto, Japan)
were used for this study. After a brief exposure to isoflurane
(Abbott Lab, North Chicago, IL), pregnant rats were fed
50 mg=kg of all-trans RA (Sigma-Aldrich, St. Louis, MO)
dissolved in olive oil (10 mg=mL) at embryonic day 10 (E10).
Surgical procedure
Sprague-Dawley pregnant rats exposed to RA on E10 un-
derwent surgery at E18.17 General anesthesia was induced and
maintained by inhaled isoflurane. After sterile preparation, the
uterine horns were exposed through a maternal midline lapa-
rotomy. A 6-0 polypropylene suture (PDS-II; Ethicon, Somer-
ville, NJ) was passed through the uterine wall and the amniotic
membranes. The back of each fetus was exposed through a
small hysterotomy, and a gelatin sheet or composite was ap-
plied on the MMC area for each of the groups as follows
(Fig. 2A): group A—gelatin composite (gelatin sponge and
sheet) containing bFGF; group B—gelatin composite without
bFGF; group C—gelatin sheet alone; and group D—untreated.
The edge of the gelatin sheet was spot glued with a cyanoac-
rylate adhesive (Instant Krazy Glue; Krazy Glue, Columbus,
OH) for better adhesion. After the gelatin was securely ad-
herent, the fetuses were returned into the uterus. The amniotic
fluid (AF) was replaced with sterile normal saline (NS) and the
hysterotomy was closed with a purse-string suture. The uterus
was returned to the abdomen and the incision closed in two
layers with a 5-0 Vicryl running suture (Ethicon). Three to four
fetuses with MMC per pregnant rat were manipulated, and the
rest of the littermates served as controls.
Estimation of degradation of gelatin sponges in utero
Degradation of the gelatin sponges in utero was evaluated
in a separate experiment by loss of fluorescence activity. Ge-
latin sponges were prelabeled with fluorescein isothiocyanate
FIG. 2. The rat model of MMC with application of the gelatin composite. (A) Application of a gelatin composite to the MMC
defect through a hysterotomy incision and its schematic. (B) Representative photograph of an untreated fetal rat with MMC at
E21. (C) Representative photograph of a fetal rat with MMC at E21 after gelatin construct application at E18. MMC,
myelomeningocele; E21, embryonic day 21. Color images available online at www.liebertonline.com=ten.
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(FITC) by adding 1500mL of FITC (Sigma-Aldrich) solution
(1 mg=mL) to twenty 3.5 mm gelatin sponges (0.6 mg wt=per
sponge) that were expanded with 0.2 M sodium bicarbonate
buffer (pH 9.7) in 2 mL tubes. The sponges were incubated for
8 h at room temperature and then centrifuged at 8000 rpm for
10 min. The supernatant was removed and the sponges were
washed in distilled water until the supernatant was clear.
After assembly with the gelatin sheet, the FITC-labeled gelatin
composites were applied to fetuses as described above. They
were harvested on E21, and sponges and AF were taken for
fluorescence analysis. Sponges were autoclaved with 1 mL NS
in a glass tube for complete thermal dissolution. The fluores-
cence of the autoclaved solution was measured in a microplate
spectrofluorometer (Ex. 494 nm, Em 518 nm; Gemini EM;
MDS, Toronto, Canada). Each of the experimental groups and
controls was as follows: group I—sponges implanted on fe-
tuses in utero from E18 to E21; group II—sponges immersed in
AF at 368C in vitro for 3 days; group III—sponges immersed in
NS at 368C in vitro for 3 days; and group IV—unmanipulated
sponges. Five samples in each group were analyzed.
Histological analysis
Pregnant rats were euthanized by CO2 inhalation followed
by cervical dislocation at E21. The fetuses were harvested by
cesarean section. Whole fetuses were fixed in 10% neutral
buffered formalin (Sigma-Aldrich) and decalcified using Im-
munocal (Decal Chemical, Tallman, NY) for 7–10 days. After
histoprocessing, they were embedded in paraffin wax and
sectioned at 4 mm thickness. Sections were dewaxed, serially
rehydrated, and stained with hematoxylin and eosin and
Trichrome. Sections assigned for immunohistochemistry were
air-dried overnight in a 508C incubator, deparaffinized, and
rehydrated in distilled water. To block endogenous peroxi-
dase, slides were incubated for 30 min with 3% hydrogen
peroxide solution (Sigma-Aldrich). The sections were then
immersed in antigen unmasking solution pH 6.0 (Vector La-
boratories, Burlingame, CA) and microwaved (Ted Pella,
Redding, CA) for 4 min on high power, cooled at room tem-
perature for 30 min, washed in distilled water, and transferred
to phosphate-buffered saline (PBS) containing 0.1% Triton
X-100. The following primary antibodies were used: anti-
vimentin (Invitrogen, Camarillo, CA; predilute antibody);
anti-pancytokeratin (1:100; Abcam, Cambridge, MA); anti-
alpha-smooth muscle actin (a-SMA; 1:200; Abcam); anti-
collagen I (1:500; Abcam); anti-collagen III (1:400; Abcam);
hyaluronan binding protein 2 (HBP2; 1:50; LifeSpan Bio-
Sciences, Seattle, WA); anti-glial fibrillary acidic protein (GFAP;
1:100; DakoCytomation Denmark A=S, Glostrup, Denmark);
and anti-neuron-specific beta III Tubulin (1:100; Abcam).
Primary antibodies were diluted using ready-to-use anti-
body diluent (DakoCytomation Denmark A=S), and applied
over the slides and then incubated over night at 48C. On the
following day, the sections were washed three times with
PBS containing 0.1% Triton X-100 and then incubated with
horseradish peroxidase polymer conjugate broad spectrum
(diaminobenzidine [DAB]; SuperPicture; Zymed Labora-
tories, Carlsbad, CA) for 30 min at room temperature. Finally,
the sections were washed one time with PBS containing
Triton X-100, observed using Peroxidase Substrate Kit (DAB;
Vector Laboratories), counterstained with hematoxylin, de-
hydrated, and mounted using Permount (Fisher Scientific,
Pittsburgh, PA). If necessary, the images were merged into a
single image, using an Apple Macintosh computer (Mack-
intosh, Cupertino, CA) with Adobe Photoshop Elements 2.0.
(Adobe, San Jose, CA).
Evaluation of healing by assessment of epidermal
ingrowth and neovascularization in the gelatin sponge
The distance between the original keratinized epidermis
and the edge of epidermis, where the gelatin sponges were
applied, was measured to assess epidermal ingrowth us-
ing a Windows XP computer (Microsoft, Redmond, WA)
with Axio Vision 4.5. (Carl Zeiss MicroImaging, Thorn-
wood, NY). Also, the area of the gelatin sponges occupied
by red blood cells (RBCs) relative to the whole area of the
gelatin sponge was assessed using the same software as an
indicator of neovascularization.18,19
Statistical data analysis
All continuous data are presented as mean standard
deviation. Parametric data were analyzed by Student’s t-test
for comparison of two groups, and by analysis of variance
for more than two groups. Pairwise comparison after anal-
ysis of variance was adjusted with the Bonferroni procedure.
Categorical data were analyzed with Fisher’s exact test.
Statistical significance was defined as p 0.05. STATA ver-
sion 10 (College Station, TX) was used for analysis.
Results
Operative results and gross appearance
A total of 29 pregnant rats underwent operation. Four
died intraoperatively due to anesthetic complications, but no
rats delivered before scheduled harvest. The cesarean section
was performed on the remaining 25 pregnant rats, and 85
operated and 5 control fetuses underwent analysis. Of the 85
operated fetuses, there were 32 survivors (37% survival).
There was no significant difference in the survival rate among
groups (group A, 23%; group B, 22%; and group C, 31%).
Since the strength of adherence of the molded gelatin sheet to
fetal skin in water was only between 0.51 and 0.89 N by
in vitro strength testing in our preliminary studies (data not
shown), we secured the gelatin composite with cyanoacry-
late adhesive. Of the 32 survivors, the gelatin composite re-
mained adherent on 21 fetuses and had detached from
11 fetuses. Sixteen of the 21 fetuses with complete adherence
of the gelatin composite underwent analysis (group A, n¼ 6;
group B, n¼ 5; and group C, n¼ 5) and were compared to
sham operated controls (group D, n¼ 5).
Figure 2B and C shows the gross appearance of an un-
treated control fetus with MMC and a fetus with MMC who
had an adherent gelatin composite, respectively. There were
no signs of inflammation around the gelatin composite.
In vivo degradation of the gelatin sponge
Figure 3 shows the fluorescence of gelatin sponges in
different conditions. The fluorescence was significantly lower
in I (2077 432, p 0.005) than other groups, which indicates
the degradation of sponge by the in utero environment. No
significant differences in the fluorescence intensity between
groups II (32835 4483), III (28705 8666), and IV (38104
2237) were observed.
1648 WATANABE ET AL.
Histological evaluation
Cellular adherence and migration to the gelatin com-
posite. Despite the evidence of degradation in the AF, the
gelatin composites were grossly and microscopically adherent
to fetuses with MMC for 3 days (Figs. 2C and 4). At higher
magnification, cells and extracellular matrix (ECM) could be
seen as an adherent layer along the outside of the gelatin sheet
in all groups (Fig. 5). Also, cells and ECM could be seen be-
tween the fetal surface and gelatin construct. The cells stained
positively for vimentin and pancytokeratin, but not a-SMA,
suggesting that these cells were comprised of epithelial and
nonepithelial types. The ECM stained positively for hyalur-
onan binding protein 2 (HBP2) and collagen type I.
In addition to the cellular layer above the gelatin sheet,
cells and their associated ECM could be seen within the
sponges in groups where a sponge was present (Fig. 6). Cells
inside the sponges appeared to be streaming from the fetal
tissue and stained positively only for vimentin. The ECM
stained positively only for HBP2. These results were consis-
tent irrespective of the presence of bFGF.
A very minimal inflammatory response was observed
with only a few neutrophils and monocytes seen within the
sponges and in the surrounding fetal tissues. Granulation
tissue was observed underneath the gelatin sponges and
interdigitated within the margin of the sponges. However,
there were no significant fibrotic changes.
Epidermal ingrowth is increased by bFGF
Epidermal ingrowth, as determined by measuring the
distance between the original keratinized epidermis and the
edge of epidermis, was measured in the groups A and B
(Fig. 7). The epidermis appeared to elongate and thicken
underneath the gelatin sponges in both groups, but group A
(with bFGF) showed significantly greater epidermal in-
growth than group B (without bFGF) (120.67 58.45mm vs.
42.84 26.51mm, p 0.05).
FIG. 3. In vivo and in vitro degradation of the gelatin
sponge. Change in the fluorescence intensity of fluorescein-
isothiocyanate-labeled gelatin sponges 3 days after the ex-
posure to various environments. The gelatin sponges were (I)
applied on the MMC at E18; (II) immersed in AF in vitro; (III)
immersed in NS in vitro; or (IV) nonimmersed control.
*p< 0.05; significant against the fluorescence intensity of
fluorescein-isothiocyanate-labeled gelatin hydrogel sponges
in other samples. AF, amniotic fluid; NS, normal saline.
FIG. 4. Transverse sections through the MMC defect 3 days after application of the gelatin composite. Group A, gelatin
composite incorporating bFGF; group B, gelatin composite without bFGF; group C, gelatin sheet alone; and group D,
untreated MMC. An adherent gelatin sheet that resembles a pink-purple membrane can be seen adhering to the fetus
(arrows). The contained gelatin sponge demonstrates a porous structure between the fetal body and gelatin sheet (the edge of
sponge is indicated with white arrows). H&E staining; magnification,5. bFGF, basic fibroblast growth factor; H&E, he-
matoxylin and eosin. Color images available online at www.liebertonline.com=ten.
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Neovascularization in the gelatin sponge
is increased by bFGF
Numerous RBCs could be seen inside the gelatin sponges
in the groups A and B, an indirect indicator of neovascu-
larization. The percentage of the area occupied by RBCs to
the whole area of the sponge was statistically greater in the
group A than in the group B (4.81 1.78% vs. 1.05 0.73%,
p 0.05) (Fig. 8).
Assessment of exposed neural elements
Figure 9 shows that exposed neural elements and ganglia
stained positively for neuron-specific beta III Tubulin in all
groups. These results were consistent with untreated control
MMC.20,21 The neural elements in all experimental groups
and in the nonoperated controls demonstrated partial stain-
ing for GFAP as well.
Discussion
This study is the first report of the use of gelatin hydrogel
as a scaffold for promoting tissue coverage of fetal MMC.
Gelatin is a biodegradable and natural biomaterial that is a
denatured form of collagen that has several advantages. It
has been proven to be cytocompatible and can be formulated
to various shapes, such as sheets, sponges, and particles. The
kinetics of degradation can be readily controlled by changing
the extent of crosslinking. Also, it has been demonstrated
that gelatin can function as a carrier for the controlled release
of growth factors with biological activities.22–24 Gelatin
incorporating bFGF has been applied to wounds in adult
wound healing models and has been shown to promote
angiogenesis, epithelization, granulation tissue formation,
and wound closure.25–30 Based on these observations, we
reasoned that the use of gelatin hydrogel containing bFGF
might promote tissue coverage over the MMC defect and
provide a baseline for further studies to optimize the growth
factors or cellular elements required to achieve this goal.
Previous investigators have applied collagen, cellulose,
polytetrafluoroethylene, and polyglycolic acid to MMC in
the surgically created fetal sheep MMC model, demonstrat-
ing some acceleration of skin regeneration.10–13 However,
these materials do not allow the controlled release of growth
factors or promote the survival and biological function of
cellular implants and may induce significant inflammatory
response.
FIG. 5. (A) Representative H&E-stained section of the MMC defect with an adherent gelatin composite. The circle shows the
area of focus for images (B) through (H) at the edge of the fetal epidermis and zone of adherence of the gelatin sheet.
Magnification, 5. (B) H&E staining, and immunohistochemistry for (C) pancytokeratin, (D) vimentin, (E) a-SMA, (F)
hyaluronan binding protein 2 (HBP2), (G) collagen I, and (H) collagen III. Magnification,20. a-SMA, alpha-smooth muscle
actin; HBP2, hyaluronan binding protein 2. Color images available online at www.liebertonline.com=ten.
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In the present study, different formulations of gelatin
hydrogel were used to create the composites to cover the
MMC defect. The gelatin sheet was designed to act as an
adhesive covering over the MMC that would exclude AF.
The sheets were prepared with a 5% gelatin solution and 24 h
dehydrothermal crosslinking. A concentration of less than
5% gelatin resulted in sheets that were very fragile, resulting
in disruption of the applied sheet when the fetus was re-
turned to the uterine cavity. A gelatin concentration of more
than 5% resulted in noncompliant sheets that would not
conform well to the contours of the MMC. The gelatin
sponge component was designed to function as a cell scaf-
fold that allowed the controlled release of bFGF. The pore
size of the scaffold is one of the important variables con-
trolling cell migration. The sponges used in the present study
had pore sizes of 250 to 400 mm, allowing optimal cell mi-
gration into the sponge based on an in vitro cellular prolif-
eration assay (data not shown).
It has been previously shown that biologically active
growth factor can be released as a result of in vivo degra-
dation of the hydrogel and that the release profile is deter-
mined by the water content of the hydrogel and the strength
of crosslinking.22–24 Our analysis by loss of fluorescence ac-
tivity, however, demonstrated a considerable amount of
degradation in utero within 3 days (Fig. 3). This faster in vivo
degradation is likely due to enzymatic degradation by fac-
tors, such as MMP2 gelatinase present in AF.31,32 Although
the gelatin sponges became smaller by the time of harvest on
E21, they were still present and functional as a scaffold for
cellular ingrowth. In addition, the increased cellular in-
growth and neovascularization in the sponges incorporating
bFGF experimentally confirmed the in vivo release of bio-
logically active bFGF. Although the degradation profile of
our composite appeared to be adequate in this relatively
short-term rat model, it is likely that a slower degradation
profile would be optimal for human MMC.
Ideally, the gelatin composite would adhere firmly to fetal
skin in the AF environment after simple application. How-
ever, the strength of adherence of the molded gelatin sheet to
fetal skin proved inadequate to carry out surgical manipu-
lations by an open surgical technique. Therefore, a minimum
amount of cyanoacrylate adhesive was used to allow the
gelatin products to adhere firmly. Although the cyanoacry-
late adhesives did not appear to add toxicity in this study, a
more biocompatible adhesive would be required for clinical
application.
FIG. 6. (A) Representative H&E-stained section of the MMC defect with an adherent gelatin composite on top left. The circle
shows the area of focus for images (B) through (H) at the fetal skin edge and edge of the gelatin sponge. Magnification,5. (B)
H&E staining, and immunohistochemistry for (C) pancytokeratin, (D) vimentin, (E) a-SMA, (F) HBP2, (G) collagen I, and (H)
collagen III. Magnification,20. Color images available online at www.liebertonline.com=ten.
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FIG. 7. Epidermal ingrowth underneath gelatin sponges 3 days after application of gelatin composites. (A) Representative
H&E staining of MMC defect with a gelatin composite. Magnification5. The circle shows the area of magnification for (B)
and (C). (B) H&E staining focused on the epidermal ingrowth from the edge of MMC defect and (C) its immunohisto-
chemistry for pancytokeratin. Magnification,20. The arrow indicates the measured distance between the original kerati-
nized epidermis and the edge of epidermis under a gelatin sponge. Graph of the distance of epidermal ingrowth under the
composite containing bFGF (group A) and without bFGF (group B) (*p< 0.05). Color images available online at www
.liebertonline.com=ten.
FIG. 8. Neovascularization inside the gelatin sponges 3 days after application of gelatin composites. (A) Representative
H&E staining of the MMC defect covered with a gelatin composite. Magnification,5. (top) (B) Trichrome (TM) staining
focused on the areas containing the mass of red blood cells inside a gelatin sponge. Magnification,20. Graph of the area of
neovascularization in gelatin composite sponges containing bFGF (group A) and without bFGF (group B) (*p< 0.05). Color
images available online at www.liebertonline.com=ten.
1652
We observed cellular populations and associated ECMs
both covering the gelatin sheet and between the gelatin
construct and the fetal surface (Figs. 5 and 6). The cells ad-
herent to the surface of gelatin sheet expressed cytokeratin
and vimentin, but not a-SMA. This suggests that they were a
mixed population consisting of epithelial cells and none-
pithelial cells excluding smooth muscle cells, myoepithelial
cells, and myofibroblast. The ECM associated with these cells
was stained positively for HBP2 and collagen I. Although
collagen III is the predominant type of collagen in the ECM
of fetal tissues, it was not found in significant amounts in this
study.33 The expression level of hyaluronan in the matrix
appeared stronger than that of collagen I. It is well known
that hyaluronan is a major component of fetal tissues and is a
major component of the ECM observed in fetal wound
healing. Fetal fibroblasts can produce hyaluronan and hya-
luronan stimulates the migration of fibroblasts.33,34 In addi-
tion, it was found that the level of hyaluronan in the AF
ranged from 16 to 72mg=mL depending on gestational age.
The AF is known to contain amniocytes that are a mixture of
epithelial and mesenchymal cells. Given the rapid appear-
ance of this cell layer and associated matrix (within 3 days), it
is likely that this layer is derived from adherence of amnio-
cytes to the gelatin rather than overgrowth from the fetal
surface.
In contrast, cells between the fetal surface and the gelatin
sponge and within the sponge stained positively only for
vimentin and the ECM were primarily stained by HBP2.
These cells were distinguishable from the cells coating the
outside of the gelatin composites, suggesting that they are
comprised of mesenchymal cells migrating into the sponges
from the underlying fetal tissue. The amount of cellular in-
growth into the sponges appeared to be equal between
group A (with bFGF) and group B (without bFGF), but these
cells were absent in group C (gelatin sheet alone), supporting
our precept that the gelatin sponge would provide a scaffold
for cellular ingrowth.
We also observed significant differences in epidermal in-
growth underneath the gelatin sponges between gelatin
sponges with and without bFGF. It is apparent that the re-
leased bFGF appeared to stimulate epidermal cells at the
margin of the defect with the desirable effect of initiating
dermal closure of the MMC defect. Interestingly, a dramatic
difference in the area occupied by red blood cells within the
sponges was observed. This indirectly suggests that the bFGF
released stimulated angiogenesis, which has been reported in
other systems.35,36 However, in this study, direct assessment
of endothelial ingrowth could not be done due to the lack of
antiendothelial antibodies with high specificity for rat en-
dothelial cells.
A major limitation of this study is the small size and rel-
atively short gestation of the rat model. This prevented an
adequate duration of observation to confirm that durable
tissue coverage would eventually occur. In addition, we have
previously demonstrated that significant neural damage has
already occurred in this model by E18, making the timing of
fetal surgery too late for prevention of neural damage.21 Our
findings indicate that most of the exposed neural tube ele-
ments stained positively for neuron-specific beta III and a
portion of the neurons stained positively for GFAP. These
FIG. 9. (A) Representative H&E staining of MMC defect with a gelatin composite containing bFGF (group A) and (D) a
gelatin sheet alone (group C). Corresponding immunohistochemistry for (B, E) neuron-specific beta III tubulin and (C, F)
GFAP. Magnification,5. GFAP, glial fibrillary acidic protein. Color images available online at www.liebertonline.com=ten.
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findings were consistent with the staining we observed in
untreated MMC controls, suggesting that at least the gelatin
constructs and bFGF had no detrimental impact on the
neural elements.
Our precept for this study was that the tissue coverage
achieved needs to be bidirectionally impermeable to both AF
and CSF to prevent damage to neural elements and the as-
sociated Arnold-Chiari malformation, respectively. It must
also have adequate strength to prevent mechanical disruption
with fetal movement and delivery. Whether the cellular
coating over the composites and cellular ingrowth observed
beneath it in this study would have ultimately provided an
adequate tissue covering is impossible to know given the
limitations of the model. However, the present study supports
our hypothesis that gelatin hydrogel could function as a
scaffold to induce the cellular migration and the consequent
proliferation required to achieve tissue coverage from en-
dogenous cells. In addition, we anticipate further optimiza-
tion of the construct by (1) adjustment of its degradation and
adhesion characteristics; (2) screening for other growth factors
(i.e., transforming growth factor-b, epidermal growth factor
(EGF), and platelet-derived growth factor) that may further
accelerate cellular ingrowth and neovascularization; and (3)
incorporation of exogenous cellular components such as fi-
broblasts, mesenchymal stem cells, or amniocytes in the
construct. Ultimately optimal constructs developed in this
model can be tested in larger animal models of MMC such as
the sheep. Although further material and technological de-
velopment of the scaffold is needed, the present data strongly
support the future potential of a tissue engineering approach
for prenatal coverage of MMC.
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